Table 3.
Meta-analysis of studies examining treatment uptake, treatment completion and SVR among people with Hepatitis C treated in a variety of community settings or specialist hospital care
| Inclusion Criteria | Treatment Uptake | Treatment Completion | SVR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. Of studies | Heterogeneity (I2) |
Pooled estimate (95% CI) |
No. Of studies | Heterogeneity (I2) |
Pooled estimate (95% CI) | No. Of studies | Heterogeneity (I2) |
Pooled estimate (95% CI) | |
| Opioid Treatment Centres | 2 | 77.7% | 91.9 (82.2–100) | 3 | 0.0% | 82.3 (77.8–86.8) | |||
| Integrated Health System (ECHO) | 1 | Not applicable | 75.6 (68.0–83.2) | 1 | Not applicable | 96.8 (93.2–100) | 2 | 84.6% | 81.3 (66.9–95.5) |
| Telemedicine | 1 | Not applicable | 22.3 (15.8–28.8) | 1 | Not applicable | 51.4 (34.8–68.0) | |||
| Primary Care | 1 | Not applicable | 67.4 (53.9–80.9) | 1 | Not applicable | 100 (97.95–100) | 5 | 94.9% | 74.4 (60.3–88.5) |
| Pharmacies / Pharmacist Clinics | 1 | Not applicable | 66.67 (58.3–75.1) | 2 | 89.0% | 79.0 (79.2–98.9) | |||
| Specialist Care | 2 | 0.0% | 34.5 (31.79–37.29) | 5 | 96.8% | 73.46 (60.9–85.9) | |||
Abbreviations: CI, Confidence interval; SVR, Sustained virologic response
a. Random-effects method used if I2 ≥ 30%